

AJJ MEDTECH HOLDINGS LIMITED

(Incorporated in the Republic of Singapore) (Unique Entity Number: 198403368H)

PROPOSED CAPITALISATION AND PROPOSED ADOPTION OF THE AJJ PERFORMANCE SHARE PLAN 2024

- RECEIPT OF THE LISTING AND QUOTATION NOTICE FROM SINGAPORE EXCHANGE SECURITIES TRADING LIMITED ("SGX-ST")

The Board of Directors (the "Board") of AJJ Medtech Holdings Limited (the "Company") refers to:

- (a) the Company's announcement dated 8 January 2024 (SGXNet Announcement No.: SG240108OTHRNUS4) relating to the proposed capitalisation of (a) the ZJ Loan Outstanding Amount; (b) the ZYL Loan; (c) the ZYH Loan; (d) the Capitalised Acquisition Consideration; and (e) the Outstanding Sponsor Fees (the "**Proposed Capitalisation**"); and
- (b) the Company's announcement dated 18 January 2024 (SGXNET Announcement No. SG240118OTHRPEA4) relating to the queries from SGX-ST in relation to the Proposed Capitalisation,

(the "Earlier Announcements").

The Board further refers to the circular to shareholders of the Company dated 11 January 2024 (the "Circular") (SGXNET Announcement No.: SG240111XMET0BT6) issued in connection with, *inter alia*, the Proposed Capitalisation and the proposed adoption of the AJJ Performance Share Plan 2024 (the "Plan").

Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as ascribed to them in the Earlier Announcements and the Circular.

Further to the Earlier Announcements, the Board wishes to announce that SGX-ST has on 22 February 2024 granted the listing and quotation notice (the "**LQN**") to the Company for the listing of and quotation for:

- (a) 308,965,857 new ordinary shares in the capital of the Company to be allotted and issued pursuant to the Proposed Capitalisation (the "Capitalisation Shares"); and
- (b) the new Shares which may be issued from time to time pursuant to the awards under the Plan (the "**PSP Shares**"), provided that the aggregate number of PSP Shares which may be issued under the Plan and any other share option schemes or share plans of the Company then in force shall not exceed 20.0% of the issued shares capital of the Company (excluding treasury shares) from time to time,

on the Catalist Board of SGX-ST, subject to compliance with SGX-ST's listing requirements.

The Capitalisation Shares have to be placed out within seven market days from the date of the LQN.

The LQN is not to be taken as an indication of the merits of the Proposed Capitalisation, the

Capitalisation Shares, the Plan, the PSP Shares, the Company and/or its subsidiaries.

A separate announcement will be released by the Company upon the allotment and issuance of the Capitalisation Shares.

BY ORDER OF THE BOARD

Zhao Xin

Chief Executive Officer and Executive Director 26 February 2024

This announcement has been prepared by the Company and has been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited (the "**Sponsor**"). It has not been examined or approved by SGX-ST and SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Jerry Chua (Telephone Number: +65 6241 6626) at Evolve Capital Advisory Private Limited, 138 Robinson Road, #13-02, Oxley Tower, Singapore 068906.